TRAW Traws Pharma, Inc.
Financings ·
Traws can sell up to $50,000,000 of new stock to Roth over 36 months, but no shares can be sold until the SEC declares a resale registration effective. Cash was $5.0 million on June 30, 2026, and cash used in operations was $18.2 million in 2025.
Traws reports $5.0 million in cash at June 30, 2026, and says existing cash plus expected at-the-market proceeds fund planned operations into the first quarter of 2027.
Nasdaq says Traws has until January 25, 2027 to regain compliance with the minimum bid price requirement, and that its listing remains fully effective for now.
Citizens JMP Securities, LLC may sell up to $5,575,709 of Traws common stock under a July 10, 2026 prospectus supplement, the amount the company's current baby shelf limit allows.
Traws says MHRA feedback has led it to add preclinical safety information to the tivoxavir marboxil data package, which it expects to resubmit in the third quarter of 2026.
Traws says a negative review by the UK regulator has deferred its planned Phase 2a influenza challenge study, and that it is advancing backup influenza compounds.
Traws says a proprietary combination antiviral may have activity against hantavirus, Ebola and Lassa, and that it plans to work with the U.S. CDC and regional regulators in Africa.
Traws reports a net loss of $7.1 million for the quarter ended March 31, 2026, and says its private financing of up to $60 million supports operations into the first quarter of 2027.
Traws says a $10 million upfront private placement, with up to $50 million more in warrants, supports operations into the first quarter of 2027, including a planned challenge trial of tivoxavir marboxil.
Traws Pharma filed a Form NT 10-K on March 31, 2026, saying it has not yet signed any financing and needs time to assess how a deal would affect its going-concern evaluation. The notice also gives unaudited 2025 net income of about $9.2 million, driven by a $26.7 million warrant accounting gain.
Traws Pharma paid $2,350,000 in cash, in full, for assets tied to a pyrrolidine antiviral compound held by Viriom. The seller's executive chairman is Traws's own chief operating officer, and its 2024 annual report carries a going-concern warning.
Traws Pharma paid $2,350,000 in cash for intellectual property and other assets from Viriom, a company tied to its chief operating officer. The board and audit committee approved the deal and called the price fair and reasonable.
Traws Pharma raised its at-the-market limit to $7,427,749 under the baby shelf cap, after selling 42,100 shares for about $122,210. The float that sets the cap uses an $8.29 high close, while the stock closed at $1.96 on April 4, 2025.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $2.8 million | $226,000 |
| Net income (loss) | $9.2 million | -$166.5 million |
| Cash from operations | -$18.2 million | -$29.8 million |
| Cash and equivalents | $3.8 million | $21.3 million |
Our latest story on this, dated Mar 31, 2026: "Traws Pharma files NT 10-K, cites financing efforts and going concern assessment". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 14, 2026: "Traws Pharma reports Q2 2026 results and updated MHRA timeline". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jul 29, 2026: "Traws Pharma receives Nasdaq notice on $1.00 minimum bid price". The story links the filing or release it is based on. Read the story.
Traws Pharma, Inc. trades under the ticker TRAW on NASDAQ.
Traws Pharma, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Traws Pharma, Inc. is 1130598. Its filings are on SEC EDGAR.
15,368,277 shares as of 2026-08-12, per the cover page of its 10-Q filed 2026-08-14.
Our directory records Traws Pharma, Inc. under United States.
Our directory classifies Traws Pharma, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Traws Pharma, Inc. is US68232V8845.
aibio.space lists Traws Pharma, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
$2.8 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Traws Pharma, Inc. reported net income of $9.2 million for the fiscal year ended Dec 31, 2025, and used $18.2 million of cash in operations, per its annual report to the SEC.
$5.0 million in cash at Jun 30, 2026, per its 10-Q.
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a financing. SEC Form 8-K (Items 1.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 7.01,8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.07,8.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio